Pirfenex 400 mg is a potent medication containing Pirfenidone as its active ingredient, specifically designed to address the symptoms of idiopathic pulmonary fibrosis (IPF). With its higher dosage strength of 400 mg, Pirfenex offers enhanced effectiveness in slowing the progression of IPF and improving lung function. This FDA-approved treatment provides hope and relief to patients battling this chronic lung condition.
Esbriet is used in the treatment of Idiopathic Pulmonary Fibrosis. It Reduces Lungs fibrosis through downregulation of the production of growth factors and procollagens I and II.
Pirfenidone is indicated for the treatment of mild-to-moderate idiopathic pulmonary fibrosis. Pirfenidone medication is used to treat adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a long-term disease in which fibrous scar tissue continuously forms in the lungs, causing persistent cough, frequent lung infections, and severe shortness of breath.
IPF is a chronic fibrotic and inflammatory lung disease where the lung tissues become swollen and scarred over time due to the synthesis and release of certain chemicals causing difficulty in breathing. Pirfenidone is an anti-fibrotic and anti-inflammatory agent and belongs to a class of medications called pyridones. Pirfenidone relieves conditions of idiopathic pulmonary fibrosis by reducing fibroblast growth thereby relieving swelling and inflammation of the lungs.